128 related articles for article (PubMed ID: 38343206)
21. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
[TBL] [Abstract][Full Text] [Related]
22. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
23. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
[TBL] [Abstract][Full Text] [Related]
24. Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.
Ocak M; Soyer O; Buyuktiryaki B; Sekerel BE; Sahiner UM
Allergol Immunopathol (Madr); 2020; 48(4):368-373. PubMed ID: 32467066
[TBL] [Abstract][Full Text] [Related]
25. Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study.
Litovsky J; Hacard F; Tétart F; Boccon-Gibod I; Soria A; Staumont-Sallé D; Doutre MS; Amsler E; Mansard C; Dezoteux F; Darrigade AS; Milpied B; Bernier C; Perrot JL; Raison-Peyron N; Paryl M; Droitcourt C; Demoly P; Grosjean J; Mura T; Du-Thanh A;
J Allergy Clin Immunol Pract; 2023 Dec; 11(12):3752-3762.e2. PubMed ID: 37652349
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
Cakmak ME
Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
[TBL] [Abstract][Full Text] [Related]
27. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
[TBL] [Abstract][Full Text] [Related]
28. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Jia HX; He YL
Am J Ther; 2020; 27(5):e455-e467. PubMed ID: 32427616
[TBL] [Abstract][Full Text] [Related]
30. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.
Alizadeh Aghdam M; Knol EF; van den Elzen M; den Hartog Jager C; van Os-Medendorp H; Knulst AC; Otten HG; Röckmann H
Clin Exp Allergy; 2020 Mar; 50(3):364-371. PubMed ID: 31925825
[TBL] [Abstract][Full Text] [Related]
31. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
[TBL] [Abstract][Full Text] [Related]
32. Omalizumab withdrawal outcomes in chronic spontaneous urticaria are linked with baseline IgE and eosinophil levels.
Maoz-Segal R; Levenberg G; Levy T; Haj-Yahia S; Shavit R; Machnes-Maayan D; Lifshitz-Tunitsky Y; Niznik S; Offengenden I; Iancovich-Kidon M; Agmon-Levin N
World Allergy Organ J; 2024 May; 17(5):100905. PubMed ID: 38742157
[TBL] [Abstract][Full Text] [Related]
33. Remission of chronic urticaria in patients treated with omalizumab.
Cvenkel K; Bizjak M; Šelb J; Košnik M
Acta Dermatovenerol Alp Pannonica Adriat; 2024 Jun; 33(2):59-61. PubMed ID: 38741391
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
35. Long-term management of chronic spontaneous urticaria with omalizumab.
Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
[TBL] [Abstract][Full Text] [Related]
36. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Omalizumab in Elderly Patients with Chronic Urticaria: Is It a Safe Therapy?
Narváez-Fernández EJ; Entrala A; Nin-Valencia A; Mir-Ihara P; Losantos-García I; Domínguez-Ortega J; González-Fernández MÁ; Quirce S; Hernández-Cano N; Cabañas R; Caballero T
Int Arch Allergy Immunol; 2023; 184(10):1003-1009. PubMed ID: 37231812
[TBL] [Abstract][Full Text] [Related]
38. The effect of at least 1-year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria.
Su O; Bahali AG; Onsun N
Dermatol Ther; 2020 Nov; 33(6):e14192. PubMed ID: 32790183
[TBL] [Abstract][Full Text] [Related]
39. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
Kulthanan K; Tuchinda P; Chularojanamontri L; Likitwattananurak C; Ungaksornpairote C
J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043
[TBL] [Abstract][Full Text] [Related]
40. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]